Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis (Relapsing Remitting): later-stage trial registry
11 of 30 indexed Multiple Sclerosis (Relapsing Remitting) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 11 currently recruiting · #519 of 28,707 conditions by registered trial count
Multiple Sclerosis (Relapsing Remitting): 30 US clinical trials tracked, 11 recruiting.
Multiple Sclerosis (Relapsing Remitting) is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Shirley Ryan AbilityLab, running 4 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis-relapsing-remitting
OPEN 11 | RECR 37% | LATE 9 | EARLY 5 | RANK #519 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Bariatric Surgery Candidate (37% recruiting · 30 trials)
Multiple Sclerosis (Relapsing Remitting) lists 11 open slots (37% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis (Relapsing Remitting) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis (Relapsing Remitting) is recruiting below its size-band peers.
11 of 30 indexed trials (36.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis (Relapsing Remitting) trials is spread across many organizations.
Shirley Ryan AbilityLab accounts for 4 of 30 trials (13.3%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis (Relapsing Remitting) enrolment sits around 100 participants.
Median target enrolment is 100 among the 30 trials that report a genuine target (sentinel values excluded). 15 of those (50%) plan for fewer than 100 participants.
-
Multiple Sclerosis (Relapsing Remitting) research is mostly interventional.
24 interventional and 6 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
MS-ResearchBiomarkerS
Cedars-Sinai Medical Center
NCT05204459
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Celgene
NCT06408259
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
The University of Texas at Dallas
NCT05958381
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Wayne State University
NCT04458688
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
University of California, San Francisco
NCT05359653
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
Georgia State University
NCT06919900
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Shirley Ryan AbilityLab
NCT06516458
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Shirley Ryan AbilityLab
NCT06390930
Intermittent Hypoxia in Persons With Multiple Sclerosis
Shirley Ryan AbilityLab
NCT06276634
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Cionic
NCT05964829
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
University of California, San Francisco
NCT06495593
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
Bristol-Myers Squibb
NCT05605782
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Immunic
NCT05201638
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Johns Hopkins University
NCT03500328
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
The Cleveland Clinic
NCT03535298
Efficacy of Diet on Quality of Life in Multiple Sclerosis
Terry L. Wahls
NCT05007483
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Biogen
NCT03958877
The Synergistic Effects of AIH and FES in Persons With MS
Shirley Ryan AbilityLab
NCT06413602
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
Mapi Pharma
NCT04121221
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Genentech
NCT02637856
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
Bayer
NCT00206648
Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse
Mallinckrodt
NCT02633033
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
Novartis Pharmaceuticals
NCT06897657
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Johns Hopkins University
NCT02988401
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Bayer
NCT00235989
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
Johns Hopkins University
NCT01667796
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
University of California, San Francisco
NCT02040298
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Massachusetts General Hospital
NCT03060759
Safety of RG2077 in Patients With Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00076934
ACTH for Fatigue in Multiple Sclerosis Patients
Providence Health & Services
NCT02315872
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 6 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis (Relapsing Remitting) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis (Relapsing Remitting) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis (Relapsing Remitting) page
30 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Multiple Sclerosis (Relapsing Remitting) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Shirley Ryan AbilityLab sponsors the most Multiple Sclerosis (Relapsing Remitting) trials on record, review their full trial history before evaluating a specific study. See Shirley Ryan AbilityLab's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis (Relapsing Remitting) condition card totals 30 registered trials; most-linked intervention Acute Intermittent Hypoxia; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.